System-Specific Biopharmaceuticals

GlaxoSmithKline plc

GSK and SBP Group enter exclusive cooperation to accelerate Bepirovirsen commercialization in China

Chongqing Tianqing and GSK Reach Commercial Cooperation on Hepatitis B Drug Bepirovirsen in Mainland China

GSK CEO to Provide Update on R&D Plans in Q2

Deutsche Bank Analyst Reiterates Hold Rating on GSK

GSK's Bepirovirsen Filing Accepted by FDA

GSK Expands Stock Repurchase Program

GSK repurchased 330,000 shares

UBS Analyst Maintains Hold Rating on GSK

GSK's Depemokimab Approved for Chronic Sinusitis with Nasal Polyps in China

Jefferies Analyst Reiterates Buy Rating on GSK

GSK's ViiV Completes Minority Equity Change

GSK's Dymista Approved in China for Severe Asthma

GSK's Beprevai Under Review in China

UK Retail Sales Decline

GSK's Bebtelovimab Application Accepted by the EMA for Review

GSK Expanding Meningitis Vaccination Program

Barclays analyst maintains sell rating on GSK

GSK's Bepirovirsen Injection Listed for Priority Review

Barclays Maintains Sell Rating on GSK with a Target Price of 19.00 Pounds

GSK Shares Repurchased

BATS

FENI

The Fidelity Enhanced International ETF (FENI) has seen a notable inflow of approximately $311.7 million, marking a 3.4% increase in outstanding units week-over-week. Key components include British American Tobacco (BTI) down 1%, AerCap Holdings (AER) down 1.6%, and GSK (GSK) up 1.1%. FENI's 52-week range is $31.80 to $40.90, with the last trade at $39.09.

nasdaq

British American Tobacco

British American Tobacco p.l.c.

Aercap Holdings NV

Fidelity Enhanced International ETF

Nasdaq

General Motors

GSK plc Sponsored ADR

Notable ETF Inflow Detected - FENI, BTI, AER, GSK

GSK plc announced that Japan's Ministry of Health, Labour and Welfare has expanded the eligible population for its RSV vaccine, Arexvy, to include adults aged 18 to 49 at increased risk for RSV disease. This follows previous approvals for older adults. The decision was supported by Phase IIIb trial data showing a comparable immune response in the younger age group. GSK shares closed at 1,859.50 pence, down 0.16%.

rttnews

Agenus

AGENUS INC

GSK: Japan's MHLW Expands Eligible Population For Arexvy

GSK executives, including the President of Europe and CFO, acquired shares under the company's Share Reward Plan on May 12, 2026, at £18.6559 per share. These transactions, while small, enhance transparency regarding insider dealings and align management with shareholders. The latest analyst rating for GSK stock is a Hold with a £21.00 price target. Spark's AI Analyst rates GSK as Neutral, citing strong financial performance but offset by weak technical momentum and financial risks. GSK is a global biopharmaceutical company focused on medicines and vaccines.

Tip Ranks

First Trust NYSE Arca Biotech Index Fd

GSK executives acquire shares under company reward plan

01177

GSK has partnered with SBP Group to launch bepirovirsen in China, leveraging CTTQ's extensive network of over 5,000 medical centers. GSK will manage regulatory and quality oversight while SBP Group handles distribution and promotional activities. Bepirovirsen, an investigational treatment for chronic hepatitis B, aims to address a significant healthcare issue affecting 75 million people in China. The drug has received priority review and breakthrough designations in multiple countries. GSK's recent acquisition of SiranBio's therapy further supports its expansion into new treatment areas.

Pharmaceutical Business Review

SBP GROUP

Ionis Pharma

GSK and SBP Group team up to advance bepirovirsen launch in China

G Sachs has raised the target price for SBP GROUPto HKD8.05, maintaining a Buy rating following the company's agreement with GlaxoSmithKline (GSK) for exclusive commercialization rights in China for the hepatitis B drug bepirovirsen. The drug, expected to be approved in 2027, aligns with the treatment needs of China's 75 million chronic hepatitis B patients. G Sachs has increased its earnings forecasts for 2027 and 2028 by 1.1% and 1.7%, respectively, reflecting the anticipated sales contribution from bepirovirsen.

AASTOCKS News

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

China Universal 800 Health Care ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Goldman Sachs

GS Hldg R

G Sachs Raises SBP GROUP  TP to HKD8.05, Maintains Buy on Introduction of GSK Hepatitis B Drug

GSK has partnered with Sino Biopharmaceutical's CTTQ to launch bepirovirsen in China, currently under regulatory review for chronic hepatitis B. The FDA approved Bizengri, a targeted therapy for a rare bile duct cancer, under the National Priority Voucher program. Additionally, President Trump has approved the firing of FDA Commissioner Marty Makary after a tumultuous tenure marked by drug rejections and political conflicts.

Pharmexec

<![CDATA[Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen]]>

GSK has partnered with Sino Biopharmaceutical to launch bepirovirsen, a potential hepatitis B treatment in China, targeting a significant patient population. This collaboration enhances GSK's infectious disease pipeline in a major healthcare market. However, investors should monitor regulatory progress, development pace, and the impact on GSK's valuation, which is currently 59.1% below fair value, with a recent share price decline of 15.2%. Concerns about dividend stability and debt levels may also affect investment decisions.

Simplywall

GSK China Hepatitis B Push Raises Questions For Valuation And Dividend Risks

GSK has entered an exclusive collaboration with Sino Biopharmaceutical (SBP Group) through its subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) to advance the launch of Bepirovirsen in mainland China. CTTQ will manage importation, distribution, and promotional activities across over 5,000 medical centers, while GSK retains marketing authorization and regulatory responsibilities. Bepirovirsen is a triple-action antisense oligonucleotide aimed at treating chronic hepatitis B, with the potential to significantly improve cure rates. The FDA has accepted a New Drug Application for Bepirovirsen, granting it Priority Review and Breakthrough Therapy Designation.

<![CDATA[GSK Enters Exclusive Collaboration with SBP Group to Accelerate Bepirovirsen at Launch in Mainland China ]]>

GlaxoSmithKline plc(GSK.UK)